All In Biotech

Free tool

FAERS Monitor: Skyrizi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761262 or its brand name (Skyrizi, Risankizumab-Rzaa). Reports on generic versions are filed under their own applications.

Reports

86,264

Serious

57,158

66% of reports

Hospitalization

19,467

Death reported

3,115

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • psoriasis8,117
  • drug ineffective3,773
  • pain3,387
  • fatigue3,279
  • arthralgia3,261
  • device issue2,933
  • pruritus2,798
  • death2,379
  • surgery2,376
  • fall2,347
  • covid-192,283
  • crohn^s disease2,240
  • diarrhoea2,169
  • headache1,994
  • rash1,569

Reports by year received

View as table
YearReports
20151
20161
20181
2019357
20201,931
20214,103
202216,392
202315,176
202414,507
202519,572
202614,223

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,967,895 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

FDA's data service returned an error (400). The numbers below may be missing or incomplete.
ReactionReportsPRR95% CI lowerChi-squared
psoriasisSignal8,11716.115.7108,399
surgerySignal2,37610.39.819,088
device issueSignal2,9338.27.918,033
covid-19Signal2,2833.23.13,437
arthralgia3,2611.91.91,453
pruritus2,7981.81.7968
fall2,3471.71.7720
pain3,3871.31.3309
fatigue3,2791.01.02
rash1,5690.90.827
diarrhoea2,1690.80.889
headache1,9940.80.7134
drug ineffective3,7730.70.7528
death2,3790.70.6395
crohn^s disease2,2400.00.0544,283

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.